SURF News and Press, Surface Oncology Inc. From 01/04/19

CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company&#...

88 companies went public in 2018 with venture capital backing. Excluding Spotify's (SPOT) direct listing, the group raised $15 billion in the IPO market. Venture exits accounted for 46% of 2018's total, and VC deal count and proceeds reached a 4-year high. The pickup in activity was driven by ...

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has been added to the NASDAQ Biotechnology Index (N...

CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning the promotion of Jessica Fees to senior vice president,...

CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning that it will host presentations at two investor confere...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. That escalated quickly. While we gave a gentle reminder last week that interest rat...

Trillium Therapeutics ( TRIL ) is a Canadian biopharmaceutical company developing fusion-proteins targeting CD47, an immune checkpoint inhibitor involved in suppression of the innate immune system (macrophages). If you are new to the CD47 story, I recommend you start here . Last week, Trill...